ICMR Patna gets nod for kala-azar drug trial : vimarsana.com

LXE408 is a tablet, believed to have better patient compliance due to a shorter regimen than the only available oral drug, Miltefosine, which is currently not being recommended as monotherapy

Related Keywords

Uttar Pradesh , India , Varanasi , Geneva , Genè , Switzerland , Patna , Bihar , Banaras , Bihar Muzaffarpur , Krishna Pandey , Shyam Sundar , Jharkhand Bihar , Indian Council Of Medical Research , Institute Of Medical Sciences , Rajendra Memorial Research Institute Of Medical Sciences , Research Centre , Bloomberg , Banaras Hindu University , Novartis , Rajendra Memorial Research Institute , Medical Sciences , Indian Council , Medical Research , Neglected Diseases , Kala Azar Medical Research Centre , Drug Controller General , Kala Azar , Drug Trial , Patna Icmr , Phase Ii Clinical Drug Trial ,